YOUR SEARCH FOR Text 186 RESULTS
1 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… Press Release View all news Incyte Reports 2023 Fourth Quarter and Year-End … endpoint was met in its randomized, placebo-controlled, Phase 2 study evaluating the safety …
2 of Total
Dermatology Research: Immune-Mediated Dermatologic Conditions | Incyte.Com
… Developing the Next Generation of Dermatology Treatments Incyte’s science-first approach and … therapies to modulate immune pathways driving uncontrolled inflammation to help restore normal …
3 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Press Release View all news Incyte Reports 2024 First Quarter Financial Results … AAD Annual Meeting from its randomized, placebo-controlled, Phase 2 study evaluating the safety …
4 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Press Release View all news Incyte Reports 2024 Second Quarter Financial … AAD Annual Meeting from its randomized, placebo-controlled, Phase 2 study evaluating the safety …
5 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Press Release View all news Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs October 31, …
6 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… Press Release View all news Incyte Reports 2024 Fourth Quarter and Year-End … A Phase 3, randomized, double-blind, placebo-controlled, multi-center trial that will …
7 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Press Release View all news Incyte Reports 2024 Third Quarter Financial Results … the Phase 2 randomized, double-blind, placebo-controlled study evaluating the efficacy and …
8 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… Press Release View all news Incyte Reports Third Quarter 2025 Financial Results … of age and older whose disease is not well controlled with topical prescription therapies, …
9 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Press Release View all news Incyte Reports 2023 Second Quarter Financial … (IGA-TS) than patients treated with vehicle control. There are an estimated 2-3 million …
10 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Press Release View all news Incyte Reports 2021 Third Quarter Financial Results … age and older whose disease is not adequately controlled with topical prescription therapies, …